Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)

Fig. 1

Change in urinary glycosaminoglycan (uGAG) levels. a Absolute change and (b) percentage change from baselinea in uGAG levels in patients with data available after 1, 2 or 3 years of treatment with idursulfase. c Absolute change and (d) percentage change from baseline in uGAG levels in patients with data available at consecutive time points (year 1, year 2 and year 3 of treatment with idursulfase). Box plots illustrate the 25th, 50th (median) and 75th percentiles (boxes) and the 10th and 90th percentiles (whiskers). aThe baseline measurement was defined as the last recorded measurement in the 12 months preceding the start of idursulfase treatment. A post-baseline measurement was defined as the value recorded closest to the 1st, 2nd or 3rd-year anniversary of the baseline measurement, within 6 months either side of the anniversary date. If there were two values within equal times of the evaluation visit, the first value was used. uGAG values for each patient may have been determined by different methods; therefore, absolute changes and percentage changes from baseline in uGAG levels are presented to give an indication of general trends

Back to article page